WELLTRUST Surpasses 100,000 Patient Consents, Paving the Way for AI-Driven Clinical Trial Recruitment
核心洞察
WELLTRUST (搜索)™, a consent-based patient database managed by WELL Health Technologies, has surpassed 100,000 patient consents since its February 2026 launch, reached entirely through organic in-clinic enrollment.
HEALWELL AI's DARWEN (搜索)™ platform will match clinical trial protocols against this standing, consented patient population using continuously refreshed clinical data to accelerate recruitment.
The initiative inverts conventional recruitment by pre-consenting patients and matching them to protocols in advance, with the goal of scaling toward approximately one million consented patients.
WELL Health Technologies Corp. (搜索) and HEALWELL AI Inc. (搜索) announced on September 8, 2026 that WELLTRUST (搜索)™, a database of consented patients managed by WELL, has surpassed 100,000 patient consents since its launch in February 2026. The milestone was reached entirely through organic, in-clinic enrollment, before the activation of additional digital consent channels and patient engagement programs now being deployed. Every record in WELLTRUST™ represents a patient who has expressly consented to be contacted about clinical trials and research studies relevant to their health circumstances.
The achievement underscores what the companies describe as a strong patient appetite to participate in critical, often lifesaving research when offered a transparent, secure, and revocable consent experience. Those who prefer not to participate simply decline to opt in when provided the option.
A Consent-First Recruitment Model
Consent capture for WELLTRUST (搜索)™ is powered by OceanMD (搜索), the patient engagement and eReferral platform of WELLSTAR Technologies Corp. (搜索), WELL's healthcare technology subsidiary. OceanMD presents the WELLTRUST™ consent to patients as a step in the digital check-in workflow and records the response directly in the patient's chart as a structured, revocable record. Because OceanMD integrates across EMR platforms, consent can be captured consistently across the clinic network, which enabled the 100,000 milestone to be reached organically and is the same mechanism through which WELL expects to scale toward one million consented patients.
Derek Clark, Chief Operating Officer of WELL, said, "We are thrilled to reach this milestone so early in WELLTRUST (搜索)™'s journey. At its core, WELLTRUST™ is about giving patients a direct, trusted way to participate in research that could change their own health outcomes, and giving researchers access to a patient population that has already opted in. Every one of the over 100,000 patient consents was given freely, and every referral that comes out of WELLTRUST™ is filtered through the patient's own clinic, so the trust patients already have with their care team carries through the entire experience. Patients remain in full control of their consent at every step."
AI-Powered Trial Matching with DARWEN
HEALWELL's DARWEN (搜索)™ AI platform connects WELLTRUST (搜索)™ patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial protocols against the consented patient population. Sacha Gera, Chief Operating Officer of HEALWELL AI, commented, "What we are solving for clinical trial sponsors and providers is speed and precision at the screening stage, where clinical trials can lose significant time and efficiency. DARWEN's AI is designed to match trial protocols against a standing, consented patient population using clinical data that is continuously refreshed through connected clinic infrastructure."
Gera added that by combining AI-powered patient matching with real-time clinical data and a consent-first governance framework, WELLTRUST (搜索)™ has the potential to move trial recruitment upstream, identifying potential patients before a trial is even placed. "This technology creates a fundamentally different model for clinical trial recruitment: a pre-consented, AI-driven protocol-patient matched population connected to a live clinical network, giving study sponsors and providers a faster and more precise path to trial-ready patients," he said.
Inverting Conventional Recruitment
Participant recruitment remains the largest driver of clinical trial delays, which in turn creates inefficiencies and delays in the distribution of lifesaving care. Conventional recruitment models search for participants only after a trial is placed, often working from stale records that fail at screening. WELLTRUST (搜索)™ inverts this model by maintaining a standing, consented patient population kept current through connected clinic data that can be matched to protocols in advance using DARWEN (搜索)'s AI.
If a patient matches a clinical trial protocol, the patient's clinic reaches out to confirm whether the patient is interested in the particular trial and in having their contact information shared with the sponsor. If the patient is interested, WELL forwards the information to the sponsor, generating a pre-screened list of suitable participants.
A Three-Phase Roadmap to Scale
WELL and HEALWELL are advancing WELLTRUST (搜索)™ through a three-phase technology roadmap designed to build the infrastructure required for AI-powered clinical trial recruitment at scale. Phase 1 focuses on accelerating clinic activations across WELL's network and streamlining in-clinic and digital consent capture. Phase 2 expands EMR connectivity across WELL's 275-clinic network and extends consent capture into diagnostics, telehealth, and patient app experiences. Phase 3 targets scaling toward approximately one million consented patients, launching a full "Trial Recruitment Solved" offering for trial sponsors and providers, and pursuing international expansion, including U.S. market entry and European regulatory readiness.
WELL Health Technologies Corp. (搜索) is Canada's largest outpatient healthcare company, owning and operating approximately 275 clinics and supporting more than 5 million annual patient visits. HEALWELL AI is a healthcare artificial intelligence company focused on preventative care, with a mission to improve healthcare and save lives through early identification and detection of disease.